NCT06207253 The Antimicrobial Potential of Diclofenac Sodium as an Intracanal Medicament
| NCT ID | NCT06207253 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | British University In Egypt |
| Condition | Endodontic Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2025-11 |
| Primary Completion | 2025-12 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this randomized clinical trial is to evaluate the capability of the material to exert bacterial reduction of diclofenac sodium versus of that calcium hydroxide paste when these materials are used as intracanal medications in permanent molar teeth with chronic apical periodontitis. The main question\[s\] it aims to answer are: • Will the diclofenac sodium (NSAIDs) possess antimicrobial efficacy to be used effectively as an intracanal medicament similar to that of calcium hydroxide in primary endodontic treatment? Participants will be allocated randomly into three equal groups by using computer generated randomization, according to the type of intracanal medication.
Eligibility Criteria
Inclusion Criteria: * Patients with teeth diagnosed with apical periodontitis * Periapical Index (PAI) ≥ 2 * The teeth are restorable Exclusion Criteria: * Teeth with immature roots * Non restorable teeth * Medically compromised patients with systemic complication that would alter the treatment. * Teeth with internal/external root resorption * Patient with an allergy to diclofenac sodium